Literature DB >> 1423639

Abnormal activation and loss of suppressor T cells in the spontaneously hypertensive rat.

W Ofosu-Appiah1, C Ruggiero.   

Abstract

Suppressor T cell function in the spontaneously hypertensive rat (SHR) and normotensive Wistar Kyoto (WKY) rats was analyzed using syngeneic mixed lymphocyte reaction (SMLR) and concanavalin A (Con A) activation. A depressed SMLR was found in adult SHR but not in adult WKY. IL-2 synthesized by SHR was 40-fold lower than that of WKY, and the suppressor T cells generated in the SMLR were incapable of suppressing IgG synthesis. Precursors of cells that can be activated by Con A to become functional suppressor cells are reduced in adult SHR. Supernatant fluids derived from Con A-activated spleen cells from adult SHR failed to significantly inhibit IgG synthesis by cultures of syngeneic spleen cells compared to supernatant fluids from young SHR or WKY Con A-activated spleen cells. However, spleen cells from both adult SHR and WKY proliferated strongly and released equivalent amounts of IL-2 in response to Con A. Addition of exogenous IL-2 to the SMLR cultures in vitro restored the ability of SHR T cells to respond in the SMLR, with generation of cells capable of suppressing IgG synthesis. Administration of SHR with IL-2 in vivo also restored the suppressor T cell function in the SMLR. These results suggest a defective suppressor T cell activation and loss of suppressor T cell activity as the SHR age.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423639     DOI: 10.1016/0008-8749(92)90318-j

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  1 in total

1.  Abnormal CD161+ immune cells and retinoic acid receptor-related orphan receptor γt-mediate enhanced IL-17F expression in the setting of genetic hypertension.

Authors:  Madhu V Singh; Michael Z Cicha; Santosh Kumar; David K Meyerholz; Kaikobad Irani; Mark W Chapleau; François M Abboud
Journal:  J Allergy Clin Immunol       Date:  2017-01-16       Impact factor: 10.793

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.